BioSpace News Archive

DYSIS Smart Colposcopy is computer-aided cervical imaging that adds the DYSISmap to a standard colposcopic assessment with clinical studies showing that it helps clinicians increase detection of high-grade cervical lesions

I Peace, Inc., a Palo Alto-based biotech start-up focusing on Nobel Prize-winning induced pluripotent stem cell (iPSC) technology obtains approval from an independent Institutional Review Board (IRB) for the process of generating iPSCs—including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution—for commercial use.

Tevard Biosciences, and Zogenix (Nasdaq: ZGNX), today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.

Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of $21.00 per share.